The Target ALS Foundation has selected RUCDR Infinite Biologics to bank and distribute the foundation’s human stem cell lines for use by researchers in academia and industry worldwide.
A unit of Rutgers’ Human Genetics Institute of New Jersey, RUCDR is the world’s largest university-based biorepository. Target ALS Foundation is a privately funded non-profit foundation “entirely focused on finding treatments for patients living with ALS” or amyotrophic lateral sclerosis, a fatal neurodegenerative disease known as Lou Gehrig’s disease.
“By providing a reliable resource for high quality stem cell lines from Target ALS subjects, we anticipate that our collaboration will encourage scientists around the world to both utilize the existing cell lines as well as contribute new lines to this important collection,” said Michael Sheldon, director of the RUCDR Stem Cell Center.
Read more here.